Search Tag: Ortho Clinical Diagnostics

ICU Management

2021 20 Oct

Background  Since the end of 2019, the world has been fighting the unprecedented global COVID-19 pandemic caused by SARSCoV-2. 1 This pandemic inspired significant efforts for the development of diagnostic tests, therapeutics and vaccines. 2,3,4 As a result, multiple efficacious COVID-19 vaccines have been developed and authorized in record speed5...Read more

ICU Management

2021 19 Jul

Ortho Clinical Diagnostics, one of the world’s largest pure-play in vitro diagnostics companies has announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho’s VITROS® Critical Care menu, is now available in EU Countries, U.K. and several ASPAC and LATAM countries.* Results from Ortho’s IL-6 assay can be used...Read more

ICU Management

2021 12 Jun

Ortho Clinical Diagnostics has been actively monitoring all 26 SARS-CoV-2 variants, including Omicron, on the potential impact to the performance of the VITROS® COVID-19 Testing Solutions including: VITROS® Anti-SARS-CoV-2 Total Assay* VITROS® Anti-SARS-CoV-2 IgG Assay* VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody Test* VITROS® SARS-CoV-2...Read more

ICU Management

2021 13 Apr

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received CE Marking for its VITROS® SARS-CoV-2 Antigen Test, initially launched in October 2020. The CE Mark allows for more convenient sample collection and expanded viral transport media. Updates to Ortho’s COVID-19...Read more

ICU Management

2020 06 Dec

Ortho Clinical Diagnostics , a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, received CE Mark for its VITROS ®  B•R•A•H•M•S PCT (Procalcitonin) assay, now commercially available to help clinicians identify sepsis and other severe bacterial infections. Ortho’s newest assay is available...Read more

ICU Management

2020 26 Oct

Ortho’s new SARS-CoV-2 antigen test offers 98.9% concordance to real-time PCR tests, making it a viable alternative suitable for mass-scale testing Ortho’s new SARS-CoV-2 antigen test is the latest addition to the company’s COVID-19 solutions, which include two CE Marked and FDA EUA COVID-19 antibody tests – Total and IgG Ortho Clinical...Read more